CAPITAL STOCK

9 Months Ended

Aug. 31, 2021

CAPITAL STOCK

NOTE 3 - CAPITAL STOCK

NOTE 3 – CAPITAL STOCK

The Company is authorized to issue 700,000,000 common shares with a par value of $0.0001 per share. The Company is authorized to issue 1,000,000 preferred shares with a par value of $0.0001. There were no issuances of common stock during the current period. The change in par value has been retroactively re-stated for all periods presented.

On December 23, 2020, Mikrocoze, Inc. (the “Company”) filed a Certificate of Amendment to its Articles of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Nevada increasing the authorized shares of common stock, par value $0.001 to 500,000,000.

On June 10, 2021, Instadose Pharma Corp. (the “Company”), filed with the Secretary of State of the State of Nevada an amendment to its articles of incorporation (the “Amendment”) to increase the authorized common stock from 500,000,000 shares to 700,000,000 shares, par value $.0001 per share. The Amendment also authorized the Company to issue up to 1,000,000 shares of blank check preferred stock, par value $.0001 per share. The financial statements have been retroactively re-stated to show the change in par value.

During the period the Company agreed to sell 1,000 shares of the Company’s common stock at $1.00 per share to 10 shareholders. No cash was received and shares were issued subsequent to the period.